Valvular Aortic valve articles

Manejo quirúrgico o percutáneo de los leaks mitrales

TAVR and New Onset LBBB

TAVR and New Onset LBBB

The safety and efficacy of transcatheter aortic valve replacement (TAVR) is already established. However, it still poses a challenge for conduction disturbances, such as the need for pacemaker or new onset left bundle branch block (LBBB). The current rate for the latter ranges from approximately 11% to 19%. In most cases, 50% of LBBB reverses

Is Rehospitalization a Relevant Factor after Aortic Valve Replacement?

Patients with severe symptomatic aortic stenosis treated with aortic valve replacement might still present cardiac failure, even after successful procedures.   According to some reports, the incidence of cardiac failure after TAVR varies between 9% and 24%. The prognostic relevance of rehospitalization in these patients has not been studied yet; in fact, it remains unclear whether

¿Qué usar para medir funcionalmente una lesión coronaria en el contexto de estenosis aórtica severa?

Secondary Mitral Regurgitation: Stages of Heart Failure and Prognostic Implications after Transcatheter Edge-to-Edge Repair

We are already familiar with the strong impact of secondary mitral valve regurgitation (SMR) in survival and quality of life.  Most of these patients present heart failure (HF) with reduced ejection fraction (HFrEF). Stages of heart failure based on extra-mitral cardiac involvement has been shown relevant. There is also extensive research on aortic valve disease

Buen desempeño de la Sapien 3 en “trabajos” para los que no está diseñada

Real-World Results of Different Devices for TAVR

Transcatheter aortic valve replacement (TAVR) keeps growing in terms of the development of new devices, more extensive operator experience, and enhanced procedure planning. Nowadays, there are multiple device options, which depend on patient characteristics and operator experience. Two-arm studies compared these devices, analyzing the potential benefits of a certain valve over the others. This multicenter

Anillos aórticos pequeños, ¿Qué válvula deberíamos elegir?

Clinical Implications of the Presence of HALT in TAVR Patients: 5-Year Follow-Up

The duration of percutaneous aortic valve implants can be increasingly observed over time, regardless of their corresponding surgical risk. In the follow-up of different registries, the presence of subclinical valvular thrombosis, evidenced in tomographic studies as an increase in valvular thickness with hypoattenuation (a term known as HALT), was observed from protocolized images.  This subclinical

La reparación de la válvula mitral con Mitraclip es segura en pacientes de alto riesgo

Is the PASCAL Device Effective against MitraClip?

Mitral regurgitation (MR) is the most common valvulopathy and full medical treatment at maximal tolerated doses has been shown quite effective to treat it. However, its limited in a group of patients that require valve intervention.  At present, the ideal treatment is surgical valve replacement, which is in many cases is not viable because of

perforación coronaria en angioplastia

We Should Treat Significant Stable CAD in Patients Undergoing TAVR

Aortic stenosis is associated to significant coronary artery disease (CAD) in nearly 50% of cases.  When we decide to treat aortic disease using surgery, it has been established we should also treat heart disease.  However, when using transcatheter aortic valve replacement (TAVR), this is still unclear, given that in many occasions we see stable lesions


Is There any Difference between Modern Valves and Self and Balloon Expandable Valves?

At present TAVR is a valid alternative to treat different risk groups of patients with severe aortic stenosis.  Among the different valves, there are two types, the self-expanding (SEV) and the balloon expandable (BEV) valves, that are the most implanted and the most researched by randomized studies across different risk groups. There are different generations

Mitral Trial: 2-Year Followup

At present, an important group of patients with mitral valve disease are at high surgical risk, especially those with deteriorated bio-prosthesis, severe mitral annulus calcification or those who had received mitral annuloplasty. Percutaneous treatment with balloon expandable valves is a valid option to treat these patients, seeing as their 30 day and one-year outcomes look


Valve-in-Valve Shows Good Evolution after 2 Years

The degeneration of bioprostheses in aortic position occurs at approximately after 10 to 15 years. In this scenario, the treatment of choice used to be redo surgery, but with the evolution of transcatheter aortic valve replacement (TAVR), it became a valid alternative with a level IIa B evidence. While there are currently multiple analyses of

Inflamación crónica, enfermedad coronaria y cáncer: distintas caras de una misma moneda

We Should Start Considering Pulmonary Hypertension After TAVR

Pulmonary hypertension is associated with higher mortality after both aortic valve replacement and transcatheter aortic valve replacement (TAVR). This is a dynamic phenomenon, and what happens after TAVR —during the periprocedure— and its impact are yet to be evaluated. Researchers conducted a subanalysis of the Japanese OCEAN TAVI Registry, which included 1872 patients who were divided